PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that WORLDSymposium™ has awarded Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) ...
Clinical studies with cipaglucosidase alfa-atga did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently than younger subjects. Of the ...
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the ...
Credit: Getty Images. Pombiliti must be administered in combination with Opfolda. The Food and Drug Administration (FDA) has approved Pombiliti ™ (cipaglucosidase alfa-atga) in combination with ...
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results